Author

F. L. Locke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

M. D. Jain· 2 shared A. J. Griswold· 1 shared B. Evernden· 1 shared B. Ziccheddu· 1 shared C. A. Coughlin· 1 shared F. Maura· 1 shared G. C. Wallace· 1 shared G. J. Kimmel· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. D. Jain

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal disease

M. L. Khaled, Y. Ren, R. Kundalia, H. Alhaddad, Z. Chen, G. C. Wallace, B. Evernden, O. E. Ospina, M. Hall, M. Liu, L. N. F. Darville, V. Izumi, Y. A. Chen, S. Pilon-Thomas, P. A. Stewart, , I. Smalley

This study identifies branched-chain keto acid accumulation in leptomeningeal disease CSF, showing immune suppression and neurodegeneration, and shows that reducing BCKA improves outcomes in mouse models.

bioRxiv · Dec 18, 2023 · PreprintCancer Biology

Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy

M. D. Jain, B. Ziccheddu, C. A. Coughlin, R. Faramand, A. J. Griswold, K. M. Reid, O. Landgren, F. L. Locke, F. Maura, M. L. Davila, J. H. Schatz

This study identifies genomic factors associated with resistance to CD19 CAR-T therapy in large B-cell lymphoma by analyzing whole genome sequencing data from treated patients.

bioRxiv · Aug 25, 2021 · PreprintCancer Biology

Response to CAR T cell therapy can be explained by ecological cell dynamics and stochastic extinction events

G. J. Kimmel, F. L. Locke, P. M. Altrock

The paper develops a mathematical model to explain CAR T cell therapy outcomes by integrating ecological dynamics and stochastic extinction events, showing tumor eradication is a stochastic process.

bioRxiv · Mar 31, 2020 · PreprintCancer Biology